C-Suite Snippets: Planning For The Future Cancer Market
Executive Summary
In case you missed it: catch up with snippets from interviews published by In Vivo this week.
You may also be interested in...
What Does It Take To Launch And Lead An Oncology Biotech Today?
Oncolytic virus company Theolytics has emerged ready to raise a series A round and get its preclinical assets into human trials by 2021. CEO Charlotte Casebourne talks to In Vivo about the challenge of standing out from the crowd in oncology, how viruses have evolved as a treatment approach in cancer, and how oncolytic viruses might be able to answer the cancer drug pricing conundrum.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.